In a recent turn of events, Pfizer and BioNTech have countered GlaxoSmithKline’s (GSK) patent lawsuit concerning their COVID-19 vaccine. The pharmaceutical giants argue that GSK’s patents are unenforceable due to delays in filing patent applications, claiming that GSK adjusted its patents to encompass the COVID-19 vaccine after it had already become widely available. This legal maneuver could significantly impact the ongoing discourse about patent rights and innovation timelines within the pharmaceutical industry.
Further details on this developing story are available on Law360.